Literature DB >> 19201295

1alpha,25-Dihydroxyvitamin D(3) to skew intratumoral levels of immune inhibitory CD34(+) progenitor cells into dendritic cells.

Jonathan S Kulbersh1, Terry A Day, M Boyd Gillespie, M Rita I Young.   

Abstract

OBJECTIVES: Prior studies showed that immune inhibitory CD34(+) progenitor cells, whose numbers are increased in head and neck squamous cell carcinoma (HNSCC) patients, can be differentiated into immune stimulatory dendritic cells by culture with 1alpha,25-dihydroxyvitamin D(3) (1,25[OH](2)D(3)). This was extended to a pilot study to diminish intratumoral levels of CD34(+) progenitor cells by inducing their maturation into dendritic cells with 1,25(OH)(2)D(3). STUDY
DESIGN: Newly diagnosed HNSCC patients were untreated for 3 weeks or received 3 weeks of 1,25(OH)(2)D(3) treatment befoer surgical treatment. SUBJECTS AND METHODS: HNSCC tissue was collected by biopsy from six patients who had no prior 1,25(OH)(2)D(3) treatment and at the time of surgical treatment from six untreated patients and 11 patients who completed 1,25(OH)(2)D(3) treatment. Tissues were analyzed by immunohistochemistry for levels of CD34(+) cells and dendritic cells.
RESULTS: After 1,25(OH)(2)D(3) treatment, intratumoral levels of CD34(+) cells and levels of immature dendritic cells declined. However, levels of intratumoral mature dendritic cells increased. Clinical effects of 1,25(OH)(2)D(3) treatment are premature to analyze.
CONCLUSIONS: Treatment of HNSCC patients with 1,25(OH)(2)D(3) reduced levels of immune inhibitory CD34(+) cells while increasing maturation of dendritic cells. This supports added studies to determine the effect of 1,25(OH)(2)D(3) on intratumoral immune competence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19201295      PMCID: PMC3337726          DOI: 10.1016/j.otohns.2008.11.011

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  18 in total

1.  Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells.

Authors:  M R Young; M A Wright; Y Lozano; M M Prechel; J Benefield; J P Leonetti; S L Collins; G J Petruzzelli
Journal:  Int J Cancer       Date:  1997-02-20       Impact factor: 7.396

2.  Failure of tumor-reactive lymph node cells to kill tumor in the presence of immune-suppressive CD34+ cells can be overcome with vitamin D3 treatment to diminish CD34+ cell levels.

Authors:  K Wiers; M A Wright; K Vellody; M R Young
Journal:  Clin Exp Metastasis       Date:  1998-04       Impact factor: 5.150

Review 3.  Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers.

Authors:  M R Young; D M Lathers
Journal:  Int J Immunopharmacol       Date:  1999-04

4.  Clinical significance of defective dendritic cell differentiation in cancer.

Authors:  B Almand; J R Resser; B Lindman; S Nadaf; J I Clark; E D Kwon; D P Carbone; D I Gabrilovich
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

5.  Peripheral blood mononuclear cell (PBMC) responsiveness in patients with head and neck cancer in relation to tumour stage and prognosis.

Authors:  J H Heimdal; H J Aarstad; B Klementsen; J Olofsson
Journal:  Acta Otolaryngol       Date:  1999-03       Impact factor: 1.494

6.  Increased presence of CD34+ cells in the peripheral blood of head and neck cancer patients and their differentiation into dendritic cells.

Authors:  T Garrity; R Pandit; M A Wright; J Benefield; S Keni; M R Young
Journal:  Int J Cancer       Date:  1997-11-27       Impact factor: 7.396

7.  Distribution of dendritic cell subtypes in primary oral squamous cell carcinoma is inconsistent with a functional response.

Authors:  Rebekah K O'Donnell; Rosemarie Mick; Michael Feldman; Satoshi Hino; Yan Wang; Marcia S Brose; Ruth J Muschel
Journal:  Cancer Lett       Date:  2007-06-18       Impact factor: 8.679

8.  Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-beta and nitric oxide.

Authors:  M R Young; M A Wright; J P Matthews; I Malik; M Prechel
Journal:  J Immunol       Date:  1996-03-01       Impact factor: 5.422

9.  Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor.

Authors:  A S Pak; M A Wright; J P Matthews; S L Collins; G J Petruzzelli; M R Young
Journal:  Clin Cancer Res       Date:  1995-01       Impact factor: 12.531

10.  Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3.

Authors:  Deanne M R Lathers; Joseph I Clark; Nicholas J Achille; M Rita I Young
Journal:  Cancer Immunol Immunother       Date:  2003-11-26       Impact factor: 6.968

View more
  20 in total

Review 1.  Immunotherapy for head and neck cancer: advances and deficiencies.

Authors:  Anna-Maria De Costa; M Rita I Young
Journal:  Anticancer Drugs       Date:  2011-08       Impact factor: 2.248

Review 2.  Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer.

Authors:  Sabrin Husein Albeituni; Chuanlin Ding; Jun Yan
Journal:  Cancer J       Date:  2013 Nov-Dec       Impact factor: 3.360

3.  Use of alpha,25-dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma.

Authors:  Jarrett E Walsh; Anna-Maria Clark; Terry A Day; M Boyd Gillespie; M Rita I Young
Journal:  Hum Immunol       Date:  2010-05-16       Impact factor: 2.850

4.  Immunological modulation by 1α,25-dihydroxyvitamin D3 in patients with squamous cell carcinoma of the head and neck.

Authors:  David D Walker; Travis D Reeves; Anna-Maria de Costa; Corinne Schuyler; M Rita I Young
Journal:  Cytokine       Date:  2012-03-24       Impact factor: 3.861

5.  Is 1,25-dihydroxyvitamin D3 receptor expression a potential Achilles' heel of CD44+ oral squamous cell carcinoma cells?

Authors:  Martin Grimm; Dorothea Alexander; Adelheid Munz; Juergen Hoffmann; Siegmar Reinert
Journal:  Target Oncol       Date:  2013-01-15       Impact factor: 4.493

Review 6.  Potential therapeutic anti-tumor effect of a Salmonella-based vaccine.

Authors:  Sun-Young Chang; Yeon-Jeong Kim; Hyun-Jeong Ko
Journal:  Hum Vaccin Immunother       Date:  2013-06-03       Impact factor: 3.452

7.  1α, 25 Dihydroxyvitamin D (1,25(OH)2D) inhibits the T cell suppressive function of myeloid derived suppressor cells (MDSC).

Authors:  J C Fleet; G N Burcham; R D Calvert; B D Elzey; T L Ratliff
Journal:  J Steroid Biochem Mol Biol       Date:  2019-11-26       Impact factor: 4.292

8.  Influence of vitamin D on cancer risk and treatment: Why the variability?

Authors:  M Rita I Young; Ying Xiong
Journal:  Trends Cancer Res       Date:  2018

9.  Vitamin D deficiency in head and neck cancer patients - prevalence, prognostic value and impact on immune function.

Authors:  Florian Bochen; Benedikt Balensiefer; Sandrina Körner; Jörg Thomas Bittenbring; Frank Neumann; Armand Koch; Klaus Bumm; Anke Marx; Silke Wemmert; Georgios Papaspyrou; David Zuschlag; Jan Philipp Kühn; Basel Al Kadah; Bernhard Schick; Maximilian Linxweiler
Journal:  Oncoimmunology       Date:  2018-07-23       Impact factor: 8.110

10.  Inflammation and tumor progression: signaling pathways and targeted intervention.

Authors:  Huakan Zhao; Lei Wu; Guifang Yan; Yu Chen; Mingyue Zhou; Yongzhong Wu; Yongsheng Li
Journal:  Signal Transduct Target Ther       Date:  2021-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.